News & Publications

KemPharm® is a clinical stage, specialty pharmaceutical company engaged in the development and discovery of proprietary prodrugs that are designed to be improved versions of widely prescribed and FDA approved products.

  • 11

    Oct

    18

  • KemPharm Provides Highlights from KOL Investor Event Focused on the ADHD Treatment Landscape

  • 05

    Oct

    18

  • KemPharm Announces Pricing of Public Offering of Common Stock

  • 04

    Oct

    18

  • KemPharm Announces Proposed Public Offering of Common Stock

  • 03

    Oct

    18

  • KemPharm to Host KOL Investor Event Focused on the ADHD Treatment Landscape

  • 17

    Sep

    18

  • KemPharm Announces Positive Topline Results from Intranasal Human Abuse Potential Trial of KP415 Prodrug

  • 11

    Sep

    18

  • KemPharm Announces Positive Topline Results from Oral Human Abuse Potential Trial of KP415 Prodrug

  • 05

    Sep

    18

  • KemPharm to Present at Two Healthcare Investor Conferences During September 2018

  • 09

    Aug

    18

  • KemPharm, Inc. Reports Second Quarter 2018 Results

  • 01

    Aug

    18

  • KemPharm to Present at Canaccord Genuity 38th Annual Growth Conference

  • 31

    Jul

    18

  • KemPharm, Inc. to Report Second Quarter 2018 Results

  • 09

    Jul

    18

  • KemPharm Announces Top Line Results from KP415.E01 Efficacy and Safety Trial in Children With ADHD; KP415 Successfully Meets Primary Efficacy Endpoint

  • 10

    May

    18

  • KemPharm Announces Positive, Topline Results from an IV Human Abuse Potential Trial with KP415 Prodrug; Reports Q1 2018 Results